康艾注射液联合化疗治疗恶性淋巴癌的临床探讨

Kangai Injection Combined with Chemotherapy in Malignant Lymphoma

目的探讨康艾注射液联合化疗治疗恶性淋巴癌的临床疗效。方法将我院收治的恶性淋巴癌患者95例随机分组,均接受ABVD化疗方案治疗,实验组同时接受康艾注射液治疗。对比两组临床疗效和毒副反应的差异性。结果与对照组对比,我们发现实验组临床缓解率和控制率明显较高,严重毒副反应发生率较低,组间差异经统计学分析后认为有意义P<0.05。结论康艾注射液联合化疗治疗恶性淋巴癌可起到减毒增效的作用,今后可将其推广应用。

Objective To explore the Kangai injection chemotherapy clinical curative effect for the treatment of malignant lymphoma Methods Our hospital 95 cases of malignant lymphoma patients randomized, all ABVD scheme chemotherapy treatment, of clinical Results the experimental group Kangai injection therapy at the same time. Contrast the differences of two groups curative effect and adverse reaction Compared with control group, we found that the clinical remission rate higher, lower incidence of serious adverse reaction, differences between groups significant （P 〈 0.05 ） and after the control group obviously statistical analysis that the Conclusion Kangai injection in combination with chemotherapy treatment of malignant lymphoma can be attenuated synergistic effect, which can be applied in the future.